Sebastian Mayer

Biog:
After gaining his PhD from the University Cambridge, Sebastian joined Domantis Ltd, a small biotech company focussing on 3rd generation antibody fragments, which was subsequently acquired by GSK. Sebastian has worked as a protein scientist developing initial production processes for dAbs and AlbudAbTM-peptide fusions as well as on targeted delivery of payloads. Recently, Sebastian joined the AlbudAbTM externalisation team within GSK BioPharm, which is aiming to establish collaborative engagement with academia and industry.